BioNxt Solutions Inc. (CVE:BNXT) | WebDisclosure

Basculer en Français

10812	Companies
234240	Keywords
163037	Articles
125255	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 06/11/2026 at 00:30, 1 month 27 days ago

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
BioNxt Solutions Inc. announces amendment of terms for unsecured convertible debentures, extending maturity dates and issuing common share purchase warrants. For further details, visit bionxt.com

BioNxt Solutions Inc. Common Share Purchase Warrants Regulatory Approvals Debentures Maturity Dates
BRIEF

published on 05/19/2026 at 09:10, 2 months 20 days ago

BioNxt progresse dans le développement d'un film orodispersible de sémaglutide

Développement Pharmaceutique Solutions BioNxt Thérapies GLP-1 Administration Sublinguale De Médicaments Semaglutide ODF
BRIEF

published on 05/19/2026 at 09:10, 2 months 20 days ago

BioNxt Progresses in Semaglutide Oral Dissolvable Film Development

Pharmaceutical Development BioNxt Solutions GLP-1 Therapies Sublingual Drug Delivery Semaglutide ODF
PRESS RELEASE

published on 05/19/2026 at 09:05, 2 months 20 days ago

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
BioNxt Solutions Inc. announces advancement of Semaglutide oral dissolvable film program into active pharmaceutical development phase, targeting growing GLP-1 market. Company leverages expertise in drug delivery systems for chronic diseases

BioNxt Solutions Inc. Oral Dissolvable Film Drug Delivery Systems Semaglutide GLP-1 Market
BRIEF

published on 04/28/2026 at 09:10, 3 months 10 days ago

BioNxt Explores Psychedelic Drug Delivery Advances

Drug Delivery Technology Mental Health Treatments BioNxt Solutions Regulatory Developments Psychedelic Therapeutics
BRIEF

published on 04/28/2026 at 09:10, 3 months 10 days ago

BioNxt explore les avancées en matière d'administration de drogues psychédéliques

Technologie D'administration De Médicaments Solutions BioNxt Évolutions Réglementaires Thérapie Psychédélique Traitements De Santé Mentale
PRESS RELEASE

published on 04/28/2026 at 09:05, 3 months 10 days ago

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
BioNxt Solutions Inc. is exploring applying its drug delivery tech to psychedelic therapeutics amid global momentum. Market opportunity in mental health treatments highlighted

BioNxt Solutions Inc. Mental Health Disorders Drug Delivery Technologies Psychedelic Therapeutics Advanced Drug Delivery
BRIEF

published on 04/14/2026 at 09:10, 3 months 24 days ago

BioNxt Commences GMP Manufacturing for Multiple Sclerosis Treatment

Clinical Trials Multiple Sclerosis GMP Manufacturing BioNxt Solutions Sublingual Cladribine
BRIEF

published on 04/14/2026 at 09:10, 3 months 24 days ago

BioNxt lance la production conforme aux BPF pour le traitement de la sclérose en plaques

Essais Cliniques Sclérose En Plaques Solutions BioNxt Cladribine Sublinguale Fabrication Conforme Aux BPF
PRESS RELEASE

published on 04/14/2026 at 09:05, 3 months 24 days ago

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
BioNxt announces successful completion of GMP manufacturing for sublingual Cladribine oral thin film, advancing to clinical-stage execution. Company aims to treat MS and neurodegenerative diseases

GMP Manufacturing Sublingual Cladribine MS Treatment BioNxt Clinical-stage Execution

Accesswire

Published on 08/08/2026 at 00:00, 10 hours 25 minutes ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 11 hours 10 minutes ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 11 hours 25 minutes ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 11 hours 55 minutes ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 12 hours 10 minutes ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 23:21, 11 hours 4 minutes ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 14 hours 55 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 15 hours 10 minutes ago

ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 16 hours 15 minutes ago

Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 16 hours 25 minutes ago

E-PANGO: Composition du capital au 31 juillet 2026

Les Echos

Published on 08/07/2026 at 18:54, 15 hours 31 minutes ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 15 hours 31 minutes ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 15 hours 45 minutes ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 15 hours 45 minutes ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 16 hours 25 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE